First and foremost, the data came from a Phase 3 trial. This late stage trial is usually the last step before a submission to regulatory authorities for approval and commercialization. In this particular case, Myovant Sciences pointed to a submission in the second quarter of 2020, which is just around the corner.
If all goes well, the company will receive approval for the treatment and have the drug on the market relatively soon. Of course, that’s exciting as it means that revenue may be around the corner.
On that note, if all goes well, revenues could be massive. The truth of the matter is that advanced prostate cancer is a very difficult form of cancer to treat with a high mortality rate.
Considering the data, if all is as it seems, this will be the best treatment on the market and will likely become the standard of care for this patient population. That opens the door to hundreds of millions of dollars in potential revenue for MYOV annually.
All in all, this is an opportunity that’s hard to ignore, and the market is seeing that opportunity clearly!
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
Don’t Miss The Next Big Story!
Join our free mailing list below to receive real-time news alerts!